alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 4.2


 


AMENDMENT TO THE

BPZ ENERGY, INC. (n/k/a BPZ RESOURCES, INC.)

2007 LONG-TERM INCENTIVE COMPENSATION PLAN


 


WHEREAS, BPZ Resources, Inc. (the “Company”) adopted
and maintains the BPZ Energy, Inc. 2007 Long-Term Incentive Compensation
Plan (the “Plan”), effective as of June 4, 2007, to provide an opportunity
for its eligible employees and certain independent contractors to earn long
term incentive awards in consideration for their services;


 


WHEREAS, the Company now desires to amend the Plan to reserve
additional shares for issuance under the Plan.


 


NOW THEREFORE, effective as of August 13, 2010, the
Plan is hereby amended by replacing Section 7(a) with the following
new Section 7(a) that shall read as follows:


 


“(a)  Maximum Shares. 
Subject to adjustment as provided in this Section 7, there is
hereby reserved for issuance under the Plan up to 8,000,000 shares of Stock of
the Company.”


 


*              *              *


 


IN
WITNESS WHEREOF, BPZ Resources, Inc. has caused this Amendment to be
executed by its duly authorized representatives on this 13th day of August,
2010.


 


 


	
  By:

  	
  /s/ Manuel Pablo
  Zúñiga-Pflücker 

  	
   

  	
  By:

  	
  /s/ Edward G. Caminos

  
	
   

  	
  Manuel Pablo
  Zúñiga-Pflücker 

  	
   

  	
   

  	
  Edward G. Caminos 

  
	
   

  	
  President and Chief
  Executive Officer

  	
   

  	
   

  	
  Chief Financial Officer

  



 


1
Cynthia Martinez Montalvo 

152nd Civil District Court 

201 Caroline, Suite 250 

P.O. Box 4651 

Houston, Texas 77210 

DNRBH•Z 

Denton Nava1To Rocha Bernal Hyde & Zech, PC. 

attorneys & counselors at law • rampagelaw.com 

San Antonio I Austin I Rio Grande Valley 

2500W. William Cannon, Suite 609 I Austin.Texas 78745-5320 

v 512-279-6431 I F 512-279-6438 

July 24, 2015 

Via Electronic Notification and email 

Re: Bob Deuell v. Texas Right to Life Committee, Inc. 

(Cause No. 2014-32179 in the 152nd Judicial District Court of Harris County, Texas) 

Dear Ms. Martinez-Montalvo: 

Pursuant to Rule 35 of the Texas Rules of Appellate Procedure, our office is requesting 

that you prepare, certify and file with the First Court of Appeals the Reporter's Record with 

the transcript of hearing held on July 1, 2015 before the Hon. Judge Schaffer on Defendant's 

Motion to Dismiss, and any and all exhibits attached thereto. 

Please contact our office as to the cost for the aforementioned record and our office 

will submit payment to you immediately. Should you have any questions or concerns, please 

contact our office at (512) 279-6431. 

GEH/SMT/ha 

cc: Christopher A. Prine 

Clerk of the Court 

First Court of Appeals 

301 Fannin Street 

Houston, Texas 77002-2066 

Very truly yours, 

Denton Navarro Rocha Bernal Hyde & Zech, P.C. 

attorneys & counselors at law • rampagelaw.com 

GEORGE E. HYDE 

SCOTT M. TSCHIRHART 

Electronic Notification 

Serving all of Texas from our San Antonio, Austin and Rio Grande Valley offices 

ACCEPTED

01-15-00617-CV

FIRST COURT OF APPEALS

HOUSTON, TEXAS

7/24/2015 2:15:48 PM

CHRISTOPHER PRINE

CLERK

 FILED IN 1st COURT OF APPEALS HOUSTON, TEXAS 7/24/2015 2:15:48 PM CHRISTOPHER A. PRINE Clerk
Cynthia Martinez Montalvo 

July 24, 2015 

21 Page 

James E. "Trey" Trainor, Ill 

BEIRNE, MAYNARD & PARSON, L.L.P. 

401 W. 15th Street, Suite 845 

Austin, TX 78701 

Joseph M. Nixon 

N. Terry Adams 

BEIRNE, MAYNARD & PARSON, L.L.P. 

1300 Post Oak Blvd., 25th Floor 

Houston, TX 77056-3000 

Electronic Notification 

Electronic Notification
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 1 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 2 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 3 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 4 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 5 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 6 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 7 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 8 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 9 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 10 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 11 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 12 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 13 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 14 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 15 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 16 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 17 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 18 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 19 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 20 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 21 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 22 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 23 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 24 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 25 of 26
Case 1:07-cv-05898-RJS Document 7-4 Filed 01/25/2008 Page 26 of 26
# C_2018301EN.01003401.xml

| 27.8.2018 | EN | Official Journal of the European Union | C 301/34 |
| --- | --- | --- | --- |

27.8.2018

EN

Official Journal of the European Union

C 301/34

---

Order of the President of the General Court of 22 June 2018 — Arysta LifeScience Netherlands v Commission

(Case T-476/17 R)

((Application for interim measures - Plant protection products - Active substance diflubenzuron - Conditions of approval for placing on the market - Application for suspension of operation - Lack of urgency - Balancing of interests))

(2018/C 301/44)

Language of the case: English

Parties

Applicants: Arysta LifeScience Netherlands BV (Amsterdam, Netherlands) (represented by C. Mereu and M. Grunchard, lawyers)

Defendant: European Commission (represented by: A. Lewis, I. Naglis and G. Koleva, acting as Agents)

Re:

Application based on Articles 278 and 279 TFEU, seeking suspension of the operation of Commission Implementing Regulation (EU) 2017/855 of 18 May 2017 amending Implementing Regulation (EU) No 540/2011 as regards the conditions of approval of the active substance diflubenzuron (OJ 2017 L 128, p. 10)

Operative part of the order

| 1. | The application for interim measures is dismissed. |
| --- | --- |

1.

The application for interim measures is dismissed.

| 2. | The costs are reserved. |
| --- | --- |

2.

The costs are reserved.

---
Case 7:07-cv-05800-KMK-LMS Document 9-3 Filed 09/04/2007 Page 1 of 1
# C_2019220EN.01003501.xml

| 1.7.2019 | EN | Official Journal of the European Union | C 220/35 |
| --- | --- | --- | --- |

1.7.2019

EN

Official Journal of the European Union

C 220/35

---

Judgment of the General Court of 8 May 2019 — RW v Commission

(Case T-170/17) (1)

(Civil Service - Officials - Article 42c of the Staff Regulations - Leave in the interests of the service - Automatic retirement - Interest in bringing proceedings - Admissibility - Scope of the law - Literal, contextual and teleological interpretation)

(2019/C 220/44)

Language of the case: French

Parties

Applicant: RW (represented by: S. Orlandi and T. Martin, lawyers)

Defendant: European Commission (represented initially by G. Berscheid and A.-C. Simon, and subsequently by G. Berscheid and B. Mongin, acting as Agents)

Re:

Action under Article 270 TFEU for annulment of the Commission’s decision of 2 March 2017 to place the applicant on leave in the interests of the service pursuant to Article 42c of the Staff Regulations of Officials of the European Union and, at the same time, to require him to take compulsory retirement pursuant to subparagraph 5 of that provision.

Operative part of the judgment

The Court:

| 1. | Annuls the Commission’s decision of 2 March 2017 by which RW was placed on leave in the interests of the service and, at the same time, required to take compulsory retirement; |
| --- | --- |

1.

Annuls the Commission’s decision of 2 March 2017 by which RW was placed on leave in the interests of the service and, at the same time, required to take compulsory retirement;

| 2. | Orders the Commission to bear its own costs and to pay those incurred by RW, including those relating to the interlocutory proceedings. |
| --- | --- |

2.

Orders the Commission to bear its own costs and to pay those incurred by RW, including those relating to the interlocutory proceedings.

---

(1)  OJ C 161, 22.5.2017.

---
```

[Federal Register Volume 66, Number 96 (Thursday, May 17, 2001)]
[Notices]
[Page 27524]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-12458]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Eye Institute; Notice of Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of 
the Board of Scientific Counselors, National Eye Institute.
    The meeting will be open to the public as indicated below, with 
attendance limited to space available. Individuals who plan to attend 
and need special assistance, such as sign language interpretation or 
other reasonable accommodations, should notify the Contact Person 
listed below in advance of the meeting. The meeting will be closed to 
the public as indicated below in accordance with the provisions set 
forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, 
discussion, and evaluation of individual intramural programs and 
projects conducted by the NATIONAL EYE INSTITUTE, including 
consideration of personnel qualifications and performance, and the 
competence of individual investigators, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Board of Scientific Counselors, National Eye 
Institute,
    Date: June 4-5, 2001.
    Open: June 4, 2001, 9 a.m. to 10 a.m.
    Agenda: Opening remarks by the Director, Intramural Research 
Program, on matters concerning the intramural program of the NEI.
    Place: National Institutes of Health, 9000 Rockville Pike, 
Building 10, Room 10B16, Bethesda, MD 20892.
    Closed: June 4, 2001, 10 a.m. to 5 p.m.
    Agenda: To review and evaluate personal qualifications and 
performance, and competence of individual investigators.
    Place: National Institutes of Health, 9000 Rockville Pike, 
Building 10, Room 10B16, Bethesda, MD 20892.
    Closed: June 5, 2001, 9 a.m. to 5 p.m.
    Agenda: To review and evaluate personal qualifications and 
performance, and competence of individual investigators.
    Place: National Institutes of Health, 9000 Rockville Pike, 
Building 10, Room 10B16, Bethesda, MD 20892.
    Contact Person: Robert B. Nussenblatt, MD, Director, Intramural 
Research Program, National Eye Institute, National Institutes of 
Health, PHS, DHHS, Bethesda, MD 20892, 301-496-3123.
    Information is also available on the Institute's/Center's home 
page: www.nei.nih.gov, where an agenda and any additional 
information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program No. 93.867, Vision 
Research, National Institutes of Health, HHS)

    Dated: May 10, 2001.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 01-12458 Filed 5-16-01; 8:45 am]
BILLING CODE 4140-01-M
```
FOIA CONFIDENTIAL TREATMENT REQUESTED

July 25, 2022

(Submitted electronically via the CFTC Portal) 

Assistant Secretary of the Commission 

FOIA, Privacy and Sunshine Acts Compliance 

Commodity Futures Trading Commission

Three Lafayette Centre, 8th Floor

1155 21st Street, N.W.

Washington, DC 2058

Re: FOIA Confidential Treatment Request - Risk Management Framework Amendments -

Removing and Replacing Certain Scenarios Used in Stress Tests

Dear FOIA Compliance Staff:

In conjunction with the self-certification submitted today via the CFTC Portal by ICE Clear U.S., Inc. ("ICUS”), 

pursuant to Section 5c(c)(1) of the Commodity Exchange Act (“CEA”) and Commission Regulation 40.6(a), ICUS 

respectfully requests Confidential Treatment for all information attached to the submission until further notice, 

as more specifically described below.

***********************

Under the Freedom of Information Act (“FOIA”), 5 USC Section 552, Section 809(g) of the Dodd-Frank Wall 

Street Reform and Consumer Protection Act and pursuant to Commission Regulation 145.9(d)(5) and any other 

applicable regulations under or implementing FOIA, ICUS hereby respectfully requests that confidential 

treatment be maintained for the document, bates stamped "ICUS 2022 07 25 - 000001," until further notice. 

ICUS also requests that the Commission notify the undersigned immediately after receiving any FOIA request 

for such documents or any other court order, subpoena or summons for the same. Finally, ICUS requests that 

it be notified in the event the Commission intends to disclose such documents to Congress or to any other 

governmental agency or unit pursuant to Section 8 of the CEA or other applicable law. ICUS does not waive its 

notification rights under Section 8(f) of the CEA or other applicable law with respect to any subpoena or summons 

for such document(s).

The basis for the request is that disclosure of these document(s) would reveal confidential commercial and 

financial information of ICUS, the disclosure of which could have a material adverse effect on, and cause injury 

to, the operations and competitive position of ICUS. This request is not to be construed as a waiver of any other 

protection from disclosure or confidential treatment accorded by law, and ICUS will rely on and invoke any such 

confidentiality protection.

***********************

If you should have any questions or require further information, please contact me at (212) 748-3964 or 

Eamonn.Hahessy@ice.com.

Sincerely, 

Eamonn Hahessy

General Counsel and Chief Compliance Officer

ICE Clear U.S., Inc.
EXHIBIT 32.1


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

      In  connection  with the  Annual  Report of  Innova  Holdings,  Inc.  (the
"Company") on Form  10-KSB/A for the year ended  December 31, 2004 as filed with
the Securities  and Exchange  Commission on the date hereof (the  "Report"),  I,
Walter Weisel, Chief Executive Officer of the Company,  certify,  pursuant to 18
U.S.C.  Section 1350, as adopted  pursuant to Section 906 of the  Sarbanes-Oxley
Act of 2002, that;

      (1)   The Report fully complies with the  requirements of section 13(a) or
            15(d) of the Securities Exchange Act of 1934; and

      (2)   The  information  contained in the Report  fairly  presents,  in all
            material respects, the financial condition and results of operations
            of the Company.

      A signed  original of this written  statement  required by Section 906 has
been  provided to the Company and will be retained by the Company and  furnished
to the Securities and Exchange Commission or its staff upon request.


/s/ Walter Weisel
-------------------------
Name:  Walter Weisel
Title: Chief Executive Officer
Date:  June 22, 2005
Case 1:07-cv-04464-AKH Document 16 Filed 09/12/2007 Page 1 of 2
Case 1:07-cv-04464-AKH Document 16 Filed 09/12/2007 Page 2 of 2
EXHIBIT 10.12



AMENDMENT TO THE

SUPPLY AGREEMENT

This Amendment to the Supply Agreement (the Amendment) is made as of this 15th day of December, 2006 by and between Vascular Solutions, Inc., having an office at 6464           Sycamore Court, Minneapolis, MN 55369 (Buyer) and SAFC, an operating division of Sigma-Aldrich Inc., having an office at 3050 Spruce St., St. Louis, MO 63103, USA (Seller)  (collectively the Parties).

RECITALS

WHEREAS, Buyer and Seller are parties to the Supply Agreement dated October 18, 2004 relating to the commercial supply of thrombin solution from bovine plasma (Agreement);

WHEREAS, the Parties now wish to amend certain terms of the Agreement;

NOW THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration the sufficiency of which is acknowledged by the Parties, the Parties, intending to be legally bound hereby agree as follows:

I.          DEFINITIONS



1.1
        All capitalized terms used and not defined herein shall have the meanings ascribed thereto in the Agreement.


II.          AMENDMENTS TO AGREEMENT



2.1
        In Section 1.5 (page 2 of 23) of Agreement, change 2007to 2008.




2.2
        In Section 1.8 (page 2 of 23) of Agreement, change **to **.




2.3
        In Attachment 2 (page 21 of 23), delete the entire table (8 rows & 2 columns) and add the following:




** The appearance of a double asterisk denotes
confidential information that has been omitted from the exhibit and filed separately, accompanied by a confidential treatment
request, with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

---

Total Number of Lots Purchased in the Contract Year
        Price Per Lot


1
        **


2
        **


3 or more
        **




2.4
        Replace Attachment 1 (page 18 of 23) with the attached updated Specifications.




Vascular Solutions, Inc.
        SAFC


By:
        _________________________
        By:
        ________________________


Name:
        _________________________
        Name:
        ________________________


Title:
        _________________________
        Title:
        ________________________


Date:
        _________________________
        Date:
        ________________________






---
Case 7:07-cv-05784-KMK-LMS Document 7 Filed 10/19/2007 Page 1 of 1
[Federal Register Volume 66, Number 98 (Monday, May 21, 2001)]
[Notices]
[Pages 28034-28035]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-12742]


-----------------------------------------------------------------------

DEPARTMENT OF THE TREASURY

Internal Revenue Service


Open Meeting of Citizen Advocacy Panel, Midwest District

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: A meeting of the Midwest Citizen Advocacy Panel will be held 
in Omaha, Nebraska.

[[Page 28035]]


DATES: The meeting will be held Thursday, June 14, 2001, and Friday, 
June 15, 2001.

FOR FURTHER INFORMATION CONTACT: Sandra McQuin at 1-888-912-1227, or 
414-297-1604.

SUPPLEMENTARY INFORMATION: Notice is hereby given pursuant to Section 
10(a)(2) of the Federal Advisory Committee Act, 5 U.S.C. App. (1988) 
that an open meeting of the Citizen Advocacy Panel (CAP) will be held 
Thursday, June 14, 2001, from 9:00 a.m. to 4:00 p.m. and Friday, June 
15, 2001, from 8:00 a.m. to Noon at the Doubletree Hotel, 1616 Dodge 
Street, Omaha, Nebraska. The Citizen Advocacy Panel is soliciting 
public comment, ideas, and suggestions on improving customer service at 
the Internal Revenue Service. Public comments will be welcome during 
the meeting, or you can submit written comments to the panel by faxing 
to (414) 297-1623, or by mail to Citizen Advocacy Panel, Mail Stop 1006 
MIL, 310 West Wisconsin Avenue, Milwaukee, WI 53203-2221.
    The Agenda will include the following: Reports by the CAP sub-
groups, presentation of taxpayer issues by individual members, 
discussion of issues, and an update on the recruitment for new panel 
members.

    Note: Last minute changes to the agenda are possible and could 
prevent effective advance notice.


    Dated: May 15, 2001.
John J. Mannion,
Director, Program Planning Quality.
[FR Doc. 01-12742 Filed 5-18-01; 8:45 am]
BILLING CODE 4830-01-P
Case 1:07-cr-00561-SHS Document 2 Filed 06/22/2007 Page 1 of 4
Case 1:07-cr-00561-SHS Document 2 Filed 06/22/2007 Page 2 of 4
Case 1:07-cr-00561-SHS Document 2 Filed 06/22/2007 Page 3 of 4
Case 1:07-cr-00561-SHS Document 2 Filed 06/22/2007 Page 4 of 4
Case 7:07-cv-05947-CLB     Document 9      Filed 10/05/2007     Page 1 of 1
**Exhibit 7.1**

**Quebecor Media Inc.**

**Statement Regarding Calculation of Ratio ofEarnings to Fixed Charges as Disclosed in**

**Quebecor Media Inc.’s Annual Report on Form 20-F for the YearEnded December 31, 2011**

For the purpose of calculating the ratio of earnings to fixed charges disclosed inQuebecor Media Inc.’s Annual Report on Form 20-F for the year ended December 31, 2011, (i) earnings consist of net income (loss) plus non-controlling interest in subsidiary, income taxes, fixed charges, amortized capitalizedinterest, less interest capitalized and (ii) fixed charges consist of interest expensed and capitalized, plus amortized premiums, discounts and financing fees amortization and an estimate of the interest within rental expense.
Case 1:07-cv-04965-AKH Document 3 Filed 09/15/2008 Page 1 of 2
Case 1:07-cv-04965-AKH Document 3 Filed 09/15/2008 Page 2 of 2